The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
about
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Genetics and biology of pancreatic ductal adenocarcinomaNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyStrategies for combining immunotherapy with radiation for anticancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indications4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityCurrent clinical trials testing the combination of immunotherapy with radiotherapy.p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.New Immunotherapy Strategies in Breast Cancer.Combinations of immunotherapy and radiation in cancer therapy.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Targeting the tumor microenvironment to enhance antitumor immune responsesHidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathwaysDiallyl disulfide inhibits TNFα induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling.Inhibitory receptors as targets for cancer immunotherapyUnique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.Immunotherapy in pediatric malignancies: current status and future perspectivesTargeting CD73 in the tumor microenvironment with MEDI9447.Old game, new players: Linking classical theories to new trends in transplant immunology.Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized miceEomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy.Overcoming tumor-mediated immunosuppression.Immune checkpoint combinations from mouse to man.Immunotherapeutic approaches for cancer therapy: An updated review.Immune Therapy in GI Malignancies: A Review.OX40, OX40L and Autoimmunity: a Comprehensive Review.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.Emerging Opportunities and Challenges in Cancer Immunotherapy.Review on the immunotherapy strategies against metastatic colorectal carcinoma.Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.CD137-CD137L interaction modulates neointima formation and the phenotype transformation of vascular smooth muscle cells via NFATc1 signaling.Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells
P2860
Q26765123-F1BC8D05-6731-4DC7-A139-99A3E416238BQ26765438-4E83A758-4172-44AA-818A-5D4F836915DCQ26782566-9346D585-A98F-449A-B1D6-30A4461A941EQ26796675-45E209A7-ED31-4B17-8382-37242CAE065CQ26996518-3EF6BCEF-93FD-4720-8E6C-0D65E9BC70F7Q27012963-88E1FB5B-6759-4603-89B0-D490CD1B6349Q30356447-67ED1AE9-1840-4EAC-AF31-D8C9586FF9BBQ30422500-D72DDA71-6180-47CD-AA7B-02C336FC6E53Q33606150-39CC2743-F9C5-43C3-87CD-0212EA729AB4Q34549227-703F2F00-E7C3-49EF-924E-C4326CDDC177Q34582640-58FA3DBF-DAD5-4564-86AE-C9ACA1FDD2A5Q34658452-338CECE3-8A7F-4E30-A110-EBD707208DC6Q34978570-9180E829-3520-449F-9502-BE30B0855817Q35176307-AA473726-EC0B-4756-9A59-3A99CF528A9DQ35600057-E29C0BD3-F08E-44D8-9B90-61A93DCF64FEQ35940908-B22FCF11-4339-4EA7-8E79-96C83A343769Q35995373-13052408-2359-4437-9781-8B0C302BEAFAQ36103115-57D0144B-FF48-4331-9046-53FD7FD78E08Q36208342-BD1C5B3A-54E7-4CA9-80C7-356296E6B343Q36691818-C96EB9CB-35FA-4931-9127-8B32B91D2F45Q37224639-642B68FB-2BAF-4D9E-A389-D663D350851BQ37662989-A9EBDA6E-C00A-46E8-A2B5-CEC1FAE6FB2BQ37714634-A373A23A-6364-41FC-B1CE-D456D00768D9Q37725761-7FA22721-073B-4EB2-9495-165FFDCA00F0Q37728543-765A0DA6-6092-4C71-B579-BEB4193F725CQ38262255-BFC7D7BD-3A82-4D93-B7C8-6B9B522DB1D2Q38306150-60854E34-8C0B-41D2-A330-7A4D37EAA441Q38388102-9E30CD1C-D767-4D64-9190-D06A7EDC46A3Q38445709-A66E3358-632F-48D3-8BE0-89CACC62FE8AQ38555213-E11F644B-6AA1-47B1-98CA-3E4F9C82743EQ38752688-A3213751-1E02-4AB7-890F-A6ED844E5DD9Q38809772-CE7BC30A-0BA5-43B0-A51C-4A24F8D008EFQ38948909-99FDC725-7A6A-4117-A222-454D9671394EQ39706240-C2B12A55-4B11-48D1-9807-1D21255817D3Q40096899-E8F7BBCF-090E-49FA-ADFD-FD5916EB15F1Q40309584-C407BA80-743D-4425-A39A-98A72EA1BEC6Q40560816-5B1FAB38-B147-42ED-9383-46D605F36C32Q41701208-AF2C1419-A634-40F0-A2A8-0FC06A824E74Q41863325-B72DD8F2-E2C9-4937-9318-E7B728A0B1AAQ42718215-A6A323E9-7736-4249-B115-A3678184EF9D
P2860
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
@en
type
label
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
@en
prefLabel
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
@en
P2093
P2860
P1476
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
@en
P2093
Amy E Moran
Andrew D Weinberg
Magdalena Kovacsovics-Bankowski
P2860
P304
P356
10.1016/J.COI.2013.01.004
P577
2013-02-14T00:00:00Z